RxDoctor Payments Data

Raghukumar Thirumala, MD

Critical Care Medicine · Pittsburgh, PANPI 1730112376

Payments from drug & device makers

$1,115in general payments, 2019–2025

Across 22 payments — averaging $50.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$451
  • AstraZeneca$381
  • Pinnacle Biologics, Inc$75
  • GSK$48
  • Veran Medical Technologies, Inc.$46
  • Ambu Inc.$28
  • plus $86 from 5 others

What the payments were for

  • Travel & lodging$39736%
  • Food & beverage$70563%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,115 in reported general payments places this provider in the 70th percentile of 354 critical care medicine providers in Pennsylvania.

See all critical care medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$77,133
Medicare patients
330
Services billed
752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter440$325,052
Breztri AerosphereBudesonide/Glycopyr/Formoterol149$112,440
Breo ElliptaFluticasone/Vilanterol202$97,572
EsbrietPirfenidone11$68,475
Pirfenidone15$51,119
TezspireTezepelumab-Ekko11$46,782
Stiolto RespimatTiotropium Br/Olodaterol Hcl35$21,273
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate67$11,478
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$11,348
SymbicortBudesonide/Formoterol Fumarate45$10,927
Spiriva RespimatTiotropium Bromide11$9,543
Albuterol Sulfate HfaAlbuterol Sulfate198$5,359
DalirespRoflumilast12$5,004
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$4,999
Roflumilast31$4,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$48$433,972655 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Daliresp$381$175,153217 claims
Genentech USA, Inc.Esbriet$11$68,47511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 354 critical care medicine providers in Pennsylvania.

Other critical care medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →